Hannson L
Blood Press. 1994 Jul;3(4):248-54. doi: 10.3109/08037059409102265.
The BBB study (Swedish for Behandla Blodtryck Bättre or Treat Blood Pressure Better) was a multicenter trial designed to investigate three aspects of antihypertensive treatment: i) Is it possible to lower the diastolic blood pressure further in "well-treated" hypertensive patients through intensified therapy? ii) Can this aim be fulfilled without increasing the incidence or severity of side-effects? iii) If i) and ii) can be answered in the affirmative, will the further reduction in diastolic blood pressure be associated with a further reduction in hypertension-associated mortality and morbidity? Altogether 2127 hypertensive men and women with an average age of 59.8 years (46-71) were recruited at 142 primary health care centers in Sweden. Approximately 10,000 patient-years were accumulated. All patients had treated essential hypertension and all had diastolic blood pressures in the range 90-100 mmHg on three consecutive visits before entering the study. The patients were randomized to either intensified treatment aiming at a blood pressure < or = 80 mmHg diastolic (group A) or to unchanged therapy (group B). A difference between group A and group B in diastolic blood pressure of 7-7.5 mmHg was achieved for > 4 years. Adverse effects were studied in detail in 100 randomly selected patients from each group using a special questionnaire and a visual analogue scale. The adverse effect score fell significantly in group A but remained unchanged in group B. Regarding cardiovascular morbidity and mortality there were no significant differences between groups A and B, the total number of strokes and myocardial infarcts being 28 in group A and 29 in group B.(ABSTRACT TRUNCATED AT 250 WORDS)
BBB研究(瑞典语“Behandla Blodtryck Bättre”,意为“更好地治疗血压”)是一项多中心试验,旨在研究降压治疗的三个方面:i)通过强化治疗,能否使“治疗良好”的高血压患者的舒张压进一步降低?ii)能否在不增加副作用发生率或严重程度的情况下实现这一目标?iii)如果对i)和ii)的回答是肯定的,舒张压的进一步降低是否会导致高血压相关死亡率和发病率的进一步降低?在瑞典的142个初级卫生保健中心共招募了2127名平均年龄为59.8岁(46 - 71岁)的高血压男性和女性。累计约10000患者年。所有患者均患有原发性高血压,且在进入研究前连续三次就诊时舒张压均在90 - 100 mmHg范围内。患者被随机分为强化治疗组(目标舒张压≤80 mmHg,A组)或维持原治疗组(B组)。4年多来,A组和B组的舒张压差值达到7 - 7.5 mmHg。使用特殊问卷和视觉模拟量表对每组随机抽取的100名患者进行了详细的副作用研究。A组的副作用评分显著下降,而B组保持不变。关于心血管发病率和死亡率,A组和B组之间无显著差异,A组中风和心肌梗死总数为28例,B组为29例。(摘要截选至250字)